Heger Thomas, Strauß Stefanie, Blessing Erwin, Andrassy Martin, Erbel Christian, Müller Oliver J, Chorianopoulos Emmanuel, Pleger Sven, Leuschner Florian, Korosoglou Grigorios, Bekeredjian Raffi, Katus Hugo A, Vogel Britta
a Department of Cardiology, Angiology, and Pulmology , Heidelberg University Hospital , Heidelberg , Germany.
b SRH-Klinikum , Karlsbad / Langensteinbach , Germany.
Acta Cardiol. 2017 Aug;72(4):474-482. doi: 10.1080/00015385.2017.1335455. Epub 2017 Jul 14.
Background Vascular injury and access site complications in the contemporary setting of transcatheter aortic valve implantation (TAVI) are known to be associated with increased mortality and morbidity. The aim of our study was to analyse the feasibility and safety of percutaneous treatment of such vascular complications using a stent graft. Methods Between January 2010 and April 2013, 36 TAVI patients developed severe access site complications and underwent subsequent interventional treatment with a covered stent. Acute treatment success was confirmed by angiography immediately after the implantation of the stent graft, with clinical long-term patency follow-up being assessed by duplex ultrasound. Results Of the 36 patients evaluated, percutaneous treatment of the acute access site bleeding was successful in 35 patients (97%), with one patient requiring surgical intervention due to insufficient haemostasis after stent graft implantation. A subset of 5 patients underwent successful ipsilateral stent graft implantation, either because crossover sheath placement was not feasible (n = 1), or intentionally with an even sheathless approach in an effort to reduce vessel injury (n = 4). After a mean follow-up of 22 ± 8 months, stent graft patency was confirmed by duplex ultrasound in 13 patients with an additional 5 patients reporting to be free from symptoms and claudication. Thirteen patients died within the first 24 months after the procedure, however, none was due to access vessel complications. Five patients were lost for follow-up. Conclusions Our data confirm that endovascular treatment of access site complications related to TAVI is feasible, safe and efficacious, resulting in long-term vascular patency.
背景 在当代经导管主动脉瓣植入术(TAVI)中,血管损伤和穿刺部位并发症与死亡率和发病率的增加相关。我们研究的目的是分析使用覆膜支架经皮治疗此类血管并发症的可行性和安全性。方法 在2010年1月至2013年4月期间,36例TAVI患者出现严重穿刺部位并发症,并随后接受了覆膜支架介入治疗。在植入覆膜支架后立即通过血管造影确认急性治疗成功,并通过双功超声评估临床长期通畅情况。结果 在评估的36例患者中,35例(97%)经皮治疗急性穿刺部位出血成功,1例患者因覆膜支架植入后止血不足需要手术干预。5例患者成功进行了同侧覆膜支架植入,其中1例是因为无法放置交叉鞘,4例是为了减少血管损伤而故意采用无鞘方法。平均随访22±8个月后,双功超声确认13例患者覆膜支架通畅,另有5例患者报告无症状和跛行。然而,13例患者在术后24个月内死亡,但均非因穿刺血管并发症所致。5例患者失访。结论 我们的数据证实,TAVI相关穿刺部位并发症的血管内治疗是可行、安全且有效的,可实现长期血管通畅。